Mirae Asset Global Etfs Holdings Ltd. Moon Lake Immunotherapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 16,730 shares of MLTX stock, worth $866,279. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,730Holding current value
$866,279% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
125Shares Held
58.1MCall Options Held
102KPut Options Held
75.9K-
Bvf Inc San Francisco, CA21.8MShares$1.13 Billion29.25% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$440 Million28.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$143 Million1.66% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.56MShares$133 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.27MShares$117 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.91B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...